Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2025-12-26 @ 4:05 AM
Study NCT ID:
NCT05493618
Status:
WITHDRAWN
Last Update Posted:
2023-01-27
First Post:
2022-08-05
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Sponsor:
Hackensack Meridian Health
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
Pro2022-0093
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |